Ganciclovir and Leflunomide Combination Therapy for a Patient with Cytomegalovirus Pneumonia after Unrelated Allogenic Stem Cell Transplantation.
10.5045/kjh.2009.44.4.315
- Author:
Jae Hee LIM
1
;
Yun Nah LEE
;
Yang Seon RYU
;
Han Jo KIM
;
Kyoung Ha KIM
;
Se Hyung KIM
;
Hyun Jung KIM
;
Sang Chul LEE
;
Sang Byung BAE
;
Chan Kyu KIM
;
Kyu Taek LEE
;
Seong Kyu PARK
;
Jong Ho WON
;
Dae Sik HONG
;
Hee Sook PARK
;
Jae Seong PARK
;
You Kyoung LEE
Author Information
1. Department of Hematology-Oncology, Soonchunhyang University School of Medicine, Bucheon, Korea. skpark@schbc.ac.kr
- Publication Type:Case Report
- Keywords:
Cytomegalovirus;
Ganciclovir;
Leflunomide
- MeSH:
Biological Agents;
Cytomegalovirus;
Ganciclovir;
Humans;
Immunoglobulins;
Isoxazoles;
Pneumonia;
Stem Cell Transplantation;
Stem Cells
- From:Korean Journal of Hematology
2009;44(4):315-319
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality among transplant recipients. The first line standard therapy for CMV pneumonia is treatment with a combination of ganciclovir and immunoglobulin. Nevertheless, the mortality of CMV pneumonia is 30~70%. Leflunomide has been recently reported to have novel anti-CMV activity by inhibiting viron assembly. It is also cheaper and is more easily given orally as compared to ganciclovir. We report here on an allogenic stem cell transplant recipient who developed CMV pneumonia that was refractory to ganciclovir and immunoglobulin. The patient was successfully treated with a combination of leflunomide and ganciclovir.
